



RON CHAPMAN, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2014-16

Date: December 23, 2014

TO: LOCAL ADAP COORDINATORS
ADAP ENROLLMENT WORKERS

SUBJECT: **ADDITION OF COBICISTAT (TYBOST) TO THE ADAP FORMULARY**

Effective December 19, 2014, cobicistat (150mg) (Tybost®) tablets have been added to the ADAP formulary. Cobicistat is an antiretroviral (ARV) drug that was approved by the federal Food and Drug Administration (FDA) on September 24, 2014 for use in individuals infected with the human immunodeficiency virus (HIV). Cobicistat is a once daily cytochrome P450 (CYP) 3A inhibitor that is to be co-administered with atazanavir or darunavir (both HIV protease inhibitors) with food, and in combination with other ARVs.

With the addition of cobicistat, ADAP has 189 drugs on the formulary.

If you have any questions regarding the addition of this new ARV medication to the ADAP formulary, please contact me at (916) 449-5943.

Celia Banda-Brown, Chief
ADAP Section
Office of AIDS